-
April 28,2023QY211 gel has completed first dose enrollment in Phase Ia healthy subjects("QYB") is conducting a Phase I clinical study to evaluate the safety and preliminary efficacy of QY211 gel for the treatment of mild to moderate atopic dermatitis in healthy Chinese subjects and patients with mild to moderate atopic dermatitis. The study, officially launched on March 8, 2023, is led by Huashan Hospital of Fudan University with Professors Jing Zhang and Jinhua Xu as principal investigators, and the project is being conducted simultaneously at multiple centers across China.More -
April 28,2023QY201 Tablets for Moderate to Severe Atopic Dermatitis in Phase Ib/II Clinical Trial Completes First Patient Enrollment (FPI)(hereinafter referred to as "QYB") announced that the first patient enrollment (FPI) has been successfully completed in the Chinese Phase Ib/II clinical trial of QY201 tablets, an innovative drug for the treatment of moderate-to-severe atopic dermatitis, and the Phase Ia study of QY201 tablets in healthy subjects was completed at the end of September. Data lock.More -
April 27,2023E-nitiate Biopharmaceuticals Biologics Completes Series A Financing of 100 Million RMB In-depth layout around skin and autoimmune disease(hereinafter referred to as "QYB") announced the completion of a Series A financing round of 100 million RMB, led by Time Investment and followed by Taikun Fund, Linping State Investment and Hangzhou Golden Investment Industry Fund. This round of financing will be used to advance the clinical development of several pipelines, including QY201 and QY101, and further help the company expand its R&D pipeline.More -
April 20,2022E-nitiate Biopharmaceuticals QY101 Ointment Was Approved for Clinical Trial in The Treatment of Atopic DermatitisRecently, E-nitiate Biopharmaceuticals received the"Drug Clinical Trial Approval Notice"issued by CDE (Notice No. : 2022LP00652,2022LP00653,2022LP00654,2022LP00655), QY101 ointment approved for clinical trial in the treatment of atopic dermatitis.More -
December 10,2021E-nitiate Biopharmaceuticals Announces First 3 Subjects Dosed in Phase I Clinical Trial of QY201Recently, E-nitiate Biopharmaceuticals (Hangzhou) Co.,Ltd. (hereinafter referred to as "E-nitiate Biopharmaceuticals") announced that the first dose of QY201 was given to 3 subjects in a phase I study. QY201 is an innovative drug for the treatment of atopic dermatitis developed independently by E-nitiate Biopharmaceuticals.More
